Leaflet: information for the user
Solifenacina/Tamsulosina Normon 6mg/0.4mg modified-release EFG tablets
solifenacina succinate/tamsulosin hydrochloride
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1.What is Solifenacina/Tamsulosina Normon and what it is used for
2What you need to know before starting to take Solifenacina/Tamsulosina Normon
3.How to take Solifenacina/Tamsulosina Normon
4.Possible side effects
5.Storage of Solifenacina/Tamsulosina Normon
6.Contents of the pack and additional information
Solifenacina/Tamsulosina Normon is a combination of two different medicines called solifenacina and tamsulosina in a tablet. Solifenacina belongs to a group of medicines called anticholinergics and tamsulosina belongs to a group of medicines called alpha-blockers.
Solifenacina/Tamsulosina Normon is used in men to treat both moderate to severe filling symptoms and emptying symptoms of the lower urinary tract caused by problems related to the bladder and by an enlarged prostate (benign prostatic hyperplasia). This medicine is used when previous treatment with monotherapy for this condition did not alleviate the symptoms sufficiently.
When the prostate becomes enlarged, urinary problems (emptying symptoms) such as delayed urination (difficulty starting urination), reduced urine flow (weak stream), dripping, and sensation of incomplete bladder emptying may occur. At the same time, the bladder is also affected and contracts spontaneously at times when urination is not desired. This causes filling symptoms such as changes in bladder sensation, urgency (having a strong and sudden desire to urinate without prior warning) and having to urinate more frequently.
Solifenacina reduces involuntary bladder contractions and increases the amount of urine that the bladder can store. Therefore, you can expect to wait longer before having to go to the bathroom. Tamsulosina allows urine to pass more easily through the urethra and facilitates urination.
Do not take Solifenacina/Tamsulosina Normon
Inform your doctor if you think you have any of these conditions.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Solifenacina/Tamsulosina Normon:
Regular medical check-ups are necessary to monitor the development of the condition being treated.
This medication may affect blood pressure, which can cause dizziness, drowsiness, or rarely, fainting (orthostatic hypotension). You should sit or lie down if you experience any of these symptoms until they have disappeared.
If you are scheduled to undergo eye surgery due to cataracts or increased pressure in the eyes (glaucoma), please inform your ophthalmologist that you have previously used, are using, or plan to use solifenacina/tamsulosina. The specialist will then take the necessary precautions regarding medication and surgical techniques. Ask your doctor if you should or should not postpone or interrupt taking this medication when undergoing eye surgery for cataracts or increased pressure in the eye (glaucoma).
Children and adolescents
Do not administer this medication to children and adolescents.
Other medications and Solifenacina/Tamsulosina Normon
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
It is especially important to inform your doctor if you are using:
Taking Solifenacina/Tamsulosina Normon with food and drinks
Solifenacina/tamsulosina can be taken with or without food, according to your preferences.
Pregnancy, breastfeeding, and fertility
Solifenacina/tamsulosina is not indicated for use in women.
In men, abnormal ejaculation (alteration of ejaculation) has been reported. This means that semen does not release through the urethra, but goes to the bladder (retrograde ejaculation) or the volume of semen is reduced or non-existent (ejaculatory insufficiency). This phenomenon is harmless.
Driving and operating machines
This medication may cause dizziness, blurred vision, fatigue, and, less frequently, drowsiness. If you experience these adverse effects, do not drive or operate machines.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The maximum daily dose is one tablet containing 6 mg of solifenacina and 0.4 mg of tamsulosina, taken orally. It can be taken with or without food, according to your preference. Do not crush or chew the tablet.
If you take more Solifenacina/Tamsulosina Normon than you should
If you have taken more tablets than you were instructed to, or if someone else takes your tablets by mistake, contact your doctor, pharmacist, or hospital immediately for advice.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
In case of overdose, your doctor may treat you with activated charcoal; emergency gastric lavage may be useful if performed within one hour of the overdose. Do not induce vomiting.
The symptoms of overdose may include: dry mouth, dizziness, and blurred vision, seeing things that are not there (hallucinations), over-excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), inability to completely or partially empty the bladder or to urinate (urinary retention), and/or unwanted increase in blood pressure.
If you forget to take Solifenacina/Tamsulosina Normon
Take your next solifenacina/tamsulosina tablet as usual. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Solifenacina/Tamsulosina Normon
If you stop taking this medication, your initial symptoms may reappear or worsen. Always consult your doctor if you are considering stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The most serious side effect observed with low frequency (which may affect up to 1 in 100 men) during treatment with solifenacin succinate/tamsulosin hydrochloride in clinical studies is acute urinary retention, which consists of a sudden inability to urinate. If you think you may be experiencing it, go to your doctor immediately. You may need to stop taking this medicine.
Solifenacin/Tamsulosin may cause allergic reactions:
If you experience an allergic crisis or a severe skin reaction (for example, blistering and peeling of the skin), you should inform your doctor immediately, and stop using this medicine. Appropriate treatment and/or measures should be applied.
Other side effects:
Frequent side effects (may affect up to 1 in 10 men)
Other side effects of infrequent occurrence (may affect up to 1 in 100 men)
Rare side effects (may affect up to 1 in 1,000 men)
Very rare side effects (may affect up to 1 in 10,000 men)
Frequency not known (cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box or blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications you no longer need at the SIGRE collection point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.
Composition of Solifenacina/Tamsulosina Normon
-The active principles are solifenacin succinate and tamsulosin hydrochloride. Each modified-release tablet contains 6mg of solifenacin succinate and 0.4mg of tamsulosin hydrochloride.
-The other components are: high molecular weight macrogol, anhydrous colloidal silica (E551), magnesium stearate (E470b), calcium dihydrogen phosphate (E341), microcrystalline cellulose (E460), microcrystalline cellulose silicified
(colloidal anhydrous silica and microcrystalline cellulose), low-substitution hydroxypropyl cellulose (E463), hypromellose (E464), red iron oxide (E172), macrogol, and butylhydroxytoluene (E321).
Appearance of the product and contents of the package
Solifenacina/Tamsulosina Normon 6mg/0.4mg modified-release tablets are red, round, biconvex, film-coated tablets with "604" engraved on one face and a diameter of 9mm.
Solifenacina/Tamsulosina Normon is available in packages with PA/aluminum/PVC/aluminum blisters or in pre-cut single-dose blisters of PA/aluminum/PVC/aluminum.
Packages of 30tablets (in blisters).
Packages of 30×1tablet (in pre-cut single-dose blisters).
Only some package sizes may be commercially available.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 - 28760 Tres Cantos - Madrid (SPAIN)
Responsiblefor manufacturing
ADAMED PHARMA S.A.
ul. Marszalka Józefa Pilsudskiego 5
95-200 Pabianice
Poland
O
ADALVO LIMITED
Malta Life Sciences Park, Building 1 Level 4
Sir Temi Zammit Buildings
San Gwann SGN 3000
Malta
This medicine is authorized in themember states of the European Economic Area with the following names:
Spain:Solifenacina/Tamsulosina Normon 6mg/0.4mg modified-release tablets EFG
Revision date of this leaflet: January 2023
The detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)(http://www.aemps.gob.es/).
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.